Trial intelligence / Profile preview

Tripterygium wilfordii induction therapy for IgA nephropathy with heavy proteinuria

ChiCTR-OPN-16010028Phase 4Completed

Sponsor
Yancheng Third People's Hospital
Start
Jan 2011
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4 trial of prednisone and Tripterygium wilfordii in IgA nephropathy (IgAN) (3 arms), sponsored by Yancheng Third People's Hospital. Primary endpoint: Proteinuria. Started Jan 2011; status: completed.

02

Drugs

prednisoneTripterygium wilfordii
03

Conditions

IgA nephropathy (IgAN)

Beyond the preview

Go deeper on ChiCTR-OPN-16010028.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR-OPN-16010028.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call